Targeting the PI3K/AKT/MTOR Pathway in KSHV-associated Cancers

Infectious Agents and Cancer - United Kingdom
doi 10.1186/1750-9378-4-s2-o7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting the Akt/mTOR Pathway in Brca1-Deficient Cancers

Oncogene
Cancer ResearchGeneticsMolecular Biology
2011English

Targeting the PI3K/Akt/mTOR Signalling Pathway in Cystic Fibrosis

Scientific Reports
Multidisciplinary
2017English

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Pre-Clinical Activity of Targeting the PI3K/Akt/mTOR Pathway in Burkitt Lymphoma

Oncotarget
Oncology
2018English

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs
Cancer ResearchToxicologyOncologyPharmaceuticsPharmacology
2016English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway

Surgical Oncology Clinics of North America
SurgeryOncology
2013English

Targeting the PI3K/AKT/mTOR Signaling Axis in Children With Hematologic Malignancies

Paediatric Drugs
Child HealthPediatricsPerinatologyPharmacology
2012English

Angelica Sinensis Promotes Myotube Hypertrophy Through the PI3K/Akt/mTOR Pathway

BMC Complementary and Alternative Medicine
MedicineAlternative MedicineComplementary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy